Dynamin inhibitors induce caspase-mediated apoptosis following cytokinesis failure in human cancer cells and this is blocked by Bcl-2 overexpression by Joshi, Sanket et al.
RESEARCH Open Access
Dynamin inhibitors induce caspase-mediated
apoptosis following cytokinesis failure in human
cancer cells and this is blocked by Bcl-2
overexpression
Sanket Joshi
1,3, Antony W Braithwaite
1,2, Phillip J Robinson
1 and Megan Chircop
1*
Abstract
Background: The aim of both classical (e.g. taxol) and targeted anti-mitotic agents (e.g. Aurora kinase inhibitors) is
to disrupt the mitotic spindle. Such compounds are currently used in the clinic and/or are being tested in clinical
trials for cancer treatment. We recently reported a new class of targeted anti-mitotic compounds that do not
disrupt the mitotic spindle, but exclusively block completion of cytokinesis. This new class includes MiTMAB and
OcTMAB (MiTMABs), which are potent inhibitors of the endocytic protein, dynamin. Like other anti-mitotics,
MiTMABs are highly cytotoxic and possess anti-proliferative properties, which appear to be selective for cancer
cells. The cellular response following cytokinesis failure and the mechanistic pathway involved is unknown.
Results: We show that MiTMABs induce cell death specifically following cytokinesis failure via the intrinsic
apoptotic pathway. This involves cleavage of caspase-8, -9, -3 and PARP, DNA fragmentation and membrane
blebbing. Apoptosis was blocked by the pan-caspase inhibitor, ZVAD, and in HeLa cells stably expressing the anti-
apoptotic protein, Bcl-2. This resulted in an accumulation of polyploid cells. Caspases were not cleaved in MiTMAB-
treated cells that did not enter mitosis. This is consistent with the model that apoptosis induced by MiTMABs
occurs exclusively following cytokinesis failure. Cytokinesis failure induced by cytochalasin B also resulted in
apoptosis, suggesting that disruption of this process is generally toxic to cells.
Conclusion: Collectively, these data indicate that MiTMAB-induced apoptosis is dependent on both
polyploidization and specific intracellular signalling components. This suggests that dynamin and potentially other
cytokinesis factors are novel targets for development of cancer therapeutics.
Background
Drugs that disrupt mitotic progression are commonly
referred to as ‘anti-mitotics’ and are extensively used for
the treatment of cancer. Classical ‘anti-mitotic’ che-
motherapeutics used in the clinic target microtubules
and include the taxanes and vinca alkaloids [1]. Despite
success in the clinic, drug resistance and toxicity have
limited their effectiveness, due to the broad role of tubu-
lin in the cytoskeleton of normal and non-dividing cells
[1]. A new class of anti-mitotics have been developed
that specifically target mitotic proteins such as Aurora
kinase, polo-like kinase, kinesin spindle protein [1,2].
Such inhibitors are being characterised as potential che-
motherapeutic agents since several induce mitotic failure
leading to apoptotic cell death in cancer cells and xeno-
graft mouse cancer models [2,3]. These mitotic proteins
are either expressed only in dividing cells or apparently
function exclusively during mitosis. In contrast to classi-
cal anti-mitotics, non-dividing differentiated cells should
not be affected by such targeted inhibition, and thus they
are predicted to be more efficacious. Many of these tar-
geted inhibitors are currently in cancer clinical trials.
Despite the differences in the protein being targeted,
both classical and targeted anti-mitotics developed to
date aim to disrupt the mitotic spindle or an early stage
in mitosis.
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mitotics that do not perturb the mitotic spindle but
exclusively block cytokinesis [4]. The targeted protein for
inhibition is the endocytic protein, dynamin II (dynII).
DynII is best known for its role in membrane trafficking
processes, specifically in clathrin-mediated endocytosis
[5-7]. However, dynII also plays an essential role in the
completion of the final stage of mitosis, cytokinesis
[4-6,8-12]. We and others have developed several classes
of dynamin inhibitors including dynasore [13], dimeric
tyrphostins (Bis-Ts), long chain amines and ammonium
salts (MiTMABs (myristyl trimethyl ammonium bro-
mides)), dynoles [14-16], iminodyns [17] and pthaladyns
[18]. Characterisation of the two most potent MiTMABs,
MiTMAB and OcTMAB (collectively referred to as MiT-
MABs), revealed that they block the abscission phase of
cytokinesis causing polyploidization, which is analogous
to the dynII siRNA phenotype [4,8]. The MiTMAB dyna-
min inhibitors share many favourable characteristics with
inhibitors of Aurora kinases, Plk and KSP: (i) they do not
affect any other phase of the cell division cycle and (ii)
possess anti-proliferative and cytotoxic properties that
are selective for cancer cells [4]. Thus, targeting cytokin-
esis with dynamin inhibitors may be a promising new
approach for the treatment of cancer.
Apoptotic cell death is central to targeted anti-mitotic
compounds being highly efficacious as chemotherapeutic
agents and is thought to depend on their ability to cause
mitotic failure and subsequent accumulation of polyploid
cells [3,19-21]. The mechanism of apoptosis following
mitosis failure is poorly understood. It is thought to be
classical apoptosis, involving caspase activation and poly
(ADP-ribose) polymerase 1 (PARP1) cleavage [22]. How-
ever, cell death induced by caspase-independent mechan-
isms has been reported [23,24]. Apoptotic cell death does
not always result following mitotic failure induced by an
anti-mitotic. Various cellular responses, depending on
the cell line and inhibitor analysed have been reported
and include apoptosis, senescence and reversible mitotic
arrest [25]. An in-depth understanding of the mechan-
isms driving a particular cellular fate in response to tar-
geted anti-mitotics is crucial for rational development
and their potential application as chemotherapeutic
agents.
In this study, we aimed to determine the fate of cells
and the signalling mechanisms involved following treat-
ment with MiTMABs, which exclusively block abscission
during cytokinesis. We report that MiTMABs induce cell
death following cytokinesis failure in several cancer cells
and this was mediated by the intrinsic apoptotic pathway.
The cellular response of cancer cells to MiTMABs
appeared to correlate with expression of Bcl-2. Our
results indicate that the anti-proliferative and cytotoxic
properties of the MiTMAB dynamin inhibitors are due to
their ability to induce apoptosis following cytokinesis fail-
ure. This provides the first evidence that targeting cyto-
kinesis is a valid approach for the development of anti-
cancer agents, and that dynII inhibitors are the first class
of compounds in this new targeted anti-mitotic group.
Methods
Cell culture
HeLa, HeLa-Bcl-2 [26] and H460 cell lines were main-
tained in RPMI 1640 medium supplemented with 10%
foetal bovine serum (FBS) and 5% (P/S). HT29, SW480
and MCF-7 cell lines were maintained in Dulbecco’s
Modified Eagle’sM e d i u m( D M E M )s u p p l e m e n t e dw i t h
10% FBS and 5% P/S. All cells were grown at 37 °C in a
humidified 5% CO2 atmosphere.
Drugs
The active dynamin inhibitors, MiTMAB (also known as
tetradecyl trimethyl ammonium bromide, CAS number
119-97-7), OcTMAB (CAS number 1120-02-1; Sigma-
Aldrich, Co., St. Louis, MO), and the inactive analogue, 2-
(DiMA)EM (2-(dimethylamino) ethyl myristate; Lancaster
Synthesis, England), were prepared as 30 mM stock solu-
tions in DMSO and stored at -20°C. Cytochalasin B (cytB)
was prepared as 5 mg/ml stock solutions in DMSO and
stored at -20°C. The CDK1 small molecule inhibitor RO-
3306 was synthesised in-house as reported previously [4].
Stock solution (9 mM) of RO-3306 was prepared in
D M S Oa n ds t o r e da t- 2 0 ° C .T h ep a n - c a s p a s ei n h i b i t o r
Z-VAD-FMK (ZVAD) and the caspase-8 selective inhibi-
tor Z-IETD-FMK (IETD) were purchased from BD Bios-
ciences and used at a final concentration of 50 µM.
Cell synchronization and treatment with MiTMABs
Cells were synchronized at the G2/M boundary by treat-
m e n tw i t hR O - 3 3 0 6( 9µ M )f o r1 8h o u r s[ 4 , 8 ]a n da t
the G1/S boundary by the double thymidine block assay
[27] as previously described. Immediately following RO-
3306 or thymidine removal, cells synchronously entered
the cell cycle and were treated with MiTMABs. As a
negative control, cells were released into drug-free med-
ium, or medium containing 0.1% DMSO or the inactive
analogue 2-(DiMA)EM. As a positive control for apop-
tosis, cells were irradiated with ultraviolet (UV-C) light
at 100 J/m
2.
Cell cycle analysis by flow cytometry
Cells (5 × 10
5 cells per dish) were grown in 10 cm
dishes. Following inhibitor treatment, cells (floating and
adherent) were collected and single-cell suspensions
were fixed in 80% ice-cold ethanol at -20 °C for at least
16 hours. Cells were stained with propidium iodide and
cell cycle was analysed [4]. Cell cycle profiles were
acquired with a FACS Canto Flow Cytometer (Becton
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nm. Cell cycle profiles were analysed using FlowJo soft-
ware (v.7.1).
Where indicated, the drugs were removed by washing
three times with drug-free medium after a 6 h treat-
ment. Cells were then incubated for an additional 42 h
in drug-free medium prior to fixation and flow cytome-
try analysis.
Time-lapse analysis
Cells were seeded in 6-well plates (1 × 10
5 cells per well)
and synchronized at the G2/M boundary as described
above. Immediately following release into the cell cycle,
cells were treated with the indicated molecule and viewed
with an Olympus IX80 inverted microscope. A time-lapse
series was acquired using a fully motorised stage, 10x
objective, and Metamorph software using the time-lapse
modules. Temperature was controlled at 37°C using the
Incubator XL, providing a humidified atmosphere with
5% CO2. Images were captured every 10 minutes for 20
hours. Where indicated, a time-lapse series was acquired
in asynchronously growing cells immediately following
the addition of the indicated drug.
Immunofluorescence microscopy
Cells were fixed in ice-cold 100% methanol and immu-
nostaining was carried using the anti-a-tubulin (Clone
DM1A; Sigma) antibody [4,27]. Cells were viewed and
scored for multinucleation with a fluorescence micro-
scope (Olympus BX51). Fluorescence images were cap-
tured and processed using an Olympus IX80 inverted
microscope using 40x or 100x oil immersion lenses and
Metamorph software. Images were deconvolved using
AutoDeblur v.9.3 (AutoQuant Imaging, Watervliet, NY).
Immunoblotting
Cell lysates were prepared as described previously [28]. In
brief, cells were collected by centrifugation, washed with
PBS, then resuspended in ice-cold lysis buffer (20 mM
Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100 and EDTA-free Complete pro-
tease inhibitor cocktail (Roche)) for 30 mins. The super-
natant (cell lysate) was collected following centrifugation
at 13,000 rpm for 30 min at 4ºC. Cell lysates (50 μg) were
fractionated by SDS-PAGE for immunoblot analysis
using the following primary antibodies: Bcl-2, Bcl-XL,
Mcl-1, cleaved caspase-8, -9, -3, PARP (Cell Signaling
Tech) and b-actin (Sigma-Aldrich). Primary antibody was
detected by incubation with horseradish peroxidise-con-
jugated anti-rabbit or anti-mouse secondary antibody
(Jackson ImmunoResearch Laboratories). Blotted pro-
teins were visualized using the ECL chemiluminescence
detection system (Pierce).
Results
HeLa cells undergo apoptosis following cytokinesis failure
MiTMABs inhibit cell proliferation and reduce viability
in a range of cancer cells [4]. In HeLa cells these effects
were due to the ability of the MiTMABs to induce
apoptosis. MiTMABs also cause polyploidization by
inducing cytokinesis failure at the abscission stage [4].
Since induction of apoptosis by anti-mitotic compounds
is thought to depend on polyploidization [3,19,20], we
used time-lapse microscopy and individual cell analysis
to ask if apoptosis follows multinucleation induced by
MiTMABs. G2/M synchronized HeLa cells treated with
M i T M A B sp r o g r e s st h r o u g hm i t o s i sn o r m a l l y ,e n t e r
cytokinesis and complete membrane ingression, as pre-
viously observed [4]. However, they fail at the abscission
stage of cytokinesis resulting in cleavage furrow regres-
sion and formation of a binucleated cell (Figure 1A).
Apoptotic cell death was observed approximately 420
mins following mitosis failure as indicated by membrane
blebbing and formation of apoptotic bodies (Figure 1A).
Among the cells treated with MiTMABs that failed
cytokinesis, apoptosis occurred in a dose-dependent
manner, with 100% of cells undergoing cell death at 30
µM (Figure 1B). In contrast, the inactive MiTMAB ana-
logue, 2-(DiMA)EM, did not have a significant effect on
cell death (Figure 1B). Similar results were obtained in
asynchronous cells indicating no effect of the synchroni-
zation agent (Figure 1C). The results demonstrate that
MiTMAB-induced apoptosis occurs primarily following
cytokinesis failure. Cell death also occurred to a similar
extent as MiTMAB treatment in those cells that had
failed cytokinesis in the presence of the cytokinesis inhi-
bitor, cytochalasin B (cytB; Figure 1C). Thus, failure of
cytokinesis appears to be toxic to cells.
We next sought to determine when after cytokinesis
f a i l u r et h ec e l l sw e r ec o mmitted to apoptosis by using
flow cytometry. By 6 h after release from the G2/M
boundary, the majority of cells have entered mitosis and
completed this process albeit either successfully (two
mononucleated daughter cells) or unsuccessfully (binu-
cleated cell). At this time point, no morphological signs
of apoptosis are evident. As expected, after a 48 h treat-
ment period, OcTMAB induced apoptosis in G2/M syn-
chronized cells, as evident by an increase in the
percentage of cells with <2N DNA content (Figure 1D).
Apoptosis was still evident in cells after 48 h when
OcTMAB was removed by wash-out after only a short
6 h treatment (Figure 1D), indicating that the cells were
already committed to cell death very soon after cytokin-
esis failure and binucleate formation. This again sug-
gests that the induction of apoptosis is associated with
cytokinesis failure and not due to generalised toxicity of
the MiTMABs.
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exclusively following cytokinesis failure
Apoptosis is characterized by activation of a caspase-
dependent pathway. Therefore, we aimed to confirm the
activation of this pathway in response to MiTMABs and
to characterize the molecular components. To confirm
the caspase dependence we co-incubated MiTMABs with
the pan-caspase inhibitor ZVAD and quantified apoptosis
by flow cytometry. Treatment with ZVAD completely
blocked apoptosis induced by 10 and 30 µM MiTMABs
in G2/M synchronized HeLa cells (Figure 2A and 2B).
Thus, the presence of ZVAD protects cells treated with
MiTMABs from apoptosis. Consistent with apoptosis
occurring post-cytokinesis failure, we observed a corre-
sponding increase in the percentage of cells containing
4N and >4N DNA content in samples treated with MiT-
MABs and ZVAD compared to MiTMABs alone (Figure
2A, C and 2D). These cell populations increased with
increasing concentrations of both MiTMABs (Figure 2C
and 2D). Specifically, 6.6 ± 0.9% and 2.7 ± 0.4% of 10 and
30 µM OcTMAB-treated cells, respectively, contained
>4N DNA and in the presence of ZVAD this increased to
Figure 1 MiTMABs induce apoptosis following cytokinesis failure in Hela cells. A-B, HeLa cells were released from the G2/M boundary in
the presence of MiTMAB, OcTMAB or controls (untreated, 0.1% DMSO and 2-(DiMA)EM) at the indicated concentrations. Cells were immediately
monitored by time-lapse microscopy for 20 hours. A, Representative time-lapse images of a HeLa cell treated with 10 µM MiTMAB undergoing
mitosis are shown. This cell undergoes apoptotic cell death, characterised by membrane blebbing, 420 min after failing cytokinesis. Cytokinesis
failure was due to an inability to abscise the intracellular bridge, thus the cleavage furrow regressed resulting in formation of a binucleated cell.
The percentage of binucleated HeLa cells that underwent apoptosis following cytokinesis failure are shown (B). Graph represents mean ± S.D.
where n > 160 for each experimental condition. C, Asynchronously growing HeLa cells were monitored by time-lapse microscope for 20 h
following addition of 30 µM MiTMAB, 4.5 µg/ml cytochalsin B (cytB) or controls (untreated, 0.1% DMSO and 2-(DiMA)EM). The graph represents
mean ± S.D. of the percentage of cytokinesis failed HeLa cells that underwent apoptosis. D, G2/M synchronized HeLa cells were analysed after
48 h following exposure to OcTMAB and controls (untreated, 0.1% DMSO and 2-(DiMA)EM) for the entire duration or for only the first 6 h
(removal by washout). The graph (mean ± S.D. from two independent experiments) shows the percentage of apoptotic cells as indicated by
<2N DNA content using flow cytometry.
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Page 4 of 12Figure 2 Cell death induced by MiTMABs is blocked by the pan-caspase inhibitor, ZVAD. A-D, G2/M synchronized HeLa cells were treated
for 20 h with MiTMABs and controls (untreated, 0.1% DMSO and 2-(DiMA)EM) in the presence and absence of the pan-caspase inhibitor, ZVAD.
DNA content in these cells was analysed by flow cytometry. Representative flow cytometry histograms of propidium iodide stained control
treated (untreated and 0.1% DMSO) HeLa cells and HeLa cells treated with MiTMABs in the presence (filled histograms) and absence (empty
histograms) of ZVAD are shown (A). The percentage of cells (mean ± S.D. from two independent experiments) with < 2N (DNA fragmentation,
which is indicative of cells undergoing apoptosis; (B), 4N (C), and >4N (D) DNA content are shown. Treatment with MiTMABs + ZVAD caused a
decline in cells containing <2N DNA and a corresponding increase in cells containing ≥ 4N DNA content compared to MiTMABs alone. * p <
0.05, ** p < 0.01 (Student’s t tests). E, HeLa cells were treated as described in A except that after 8 h cells were fixed and stained for a-tubulin,
and the percentage of cells that were multinucleated was scored using immunofluorescence microscopy. Graph shows mean ± S.D. from two
independent experiments. F, Representative microscopy images of (E) illustrating multinucleated HeLa cells treated with either MiTMAB or
OcTMAB in combination with ZVAD. Red, a-tubulin. DNA, blue.
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Page 5 of 1211.2 ± 0.5% and 7.1 ± 0.7% of OcTMAB-treated cells,
respectively. Immunofluoresc e n c em i c r o s c o p ya n a l y s i s
confirmed that the cells containing ≥4N DNA were mul-
tinucleated and not trapped in G2 or mitosis phase of the
cell cycle (Figure 2E and 2F). Consistent with the flow
cytometry data, multinucleation increased in cells treated
with both MiTMABs in a dose-dependent manner and
was further increased in the presence of ZVAD (Figure
2E). This suggests that MiTMABs induce apoptosis via a
caspase-dependent pathway and that apoptosis induced
by MiTMABs occurs following cytokinesis failure.
To identify the molecular pathway involved in execut-
ing apoptotic cell death mediated by MiTMABs following
cytokinesis failure, we sought to detect activation of spe-
cific caspases. Time-lapse analysis revealed that G2/M
synchronized cells enter mitosis within 1 h and complete
this process within 2h following release from RO-3306
block (Figure 1A). In the presence of MiTMABs cells
undergo mitosis with the same timing, but fail cytokinesis
at approximately 3 h. Cell death indicated by membrane
blebbing is observed approximately 7-8 h (10-11 h post-
release from RO-3306 block) following cytokinesis failure
(Figure 1A). Therefore, we harvested cells at 8 h post
release from RO-3306 block (approx 5 h post-cytokinesis
failure) to detect activation of caspases. Immunoblotting
of MiTMABs-treated cell lysates revealed the presence of
cleaved caspase-8, -9 and -3 and cleaved PARP (Figure
3), a target of caspase-3 in the molecular pathway driving
apoptosis [29,30]. These proteins were also cleaved fol-
lowing exposure to UV as expected [31], but not after
DMSO or 2-(DiMA)EM treatment, nor in untreated cells
( F i g u r e3 ,l e f tp a n e l s ) .I nc o n t r a s tt oG 2/M synchronized
cells, caspase and PARP cleavage products were not
detected in G1/S synchronized cells following exposure
to identical MiTMAB treatment conditions (Figure 3,
right panels). In this case, cells proceed through S phase
but do not enter mitosis by 8 h and therefore cytokinesis
failure does not occur. Thus, MiTMABs-induced caspase
activation occurs exclusively following a mitotic division.
In contrast, caspase and PARP cleavage was detectable
in both synchronized cell populations exposed to UV
(Figure 3). The results indicate that cell death induced by
M i T M A B si sar e s u l to fM i T M A B - i n d u c e dc y t o k i n e s i s
failure and is mediated by a caspase-dependent pathway.
HeLa cells stably expressing Bcl-2 are resistant to
MiTMABs-induced cell death
The activation of caspase-9 in MiTMABs-treated cells
indicates that the intrinsic pathway is involved in med-
iating cell death. Caspase-9 is an initiator caspase acti-
vated following cytochrome c release from mitochondria
[32]. Anti-apoptotic Bcl-2 family of proteins are directly
responsible for maintaining mitochondrial membrane
integrity, preventing cytochrome c release in the absence
of apoptotic stimuli [33]. Therefore, we hypothesised
that high Bcl-2 expression would inhibit MiTMAB-
induced cell death. Indeed, flow cytometric quantitation
of cells with <2N DNA content revealed that MiTMAB-
induced apoptosis is completely blocked in HeLa cells
stably expressing Bcl-2, HeLa-Bcl-2 (6.8 ± 0.3% in
HeLa-Bcl-2 cells compared to 31.5 ± 0.5% in HeLa cells
treated with 30 μM OcTMAB; Figure 4A and 4B). A
corresponding increase in polyploid cells (4N and >4N
DNA content) was observed (Figure 4C and 4D), further
supporting the idea that cell death follows MiTMAB-
induced cytokinesis failure. These results are analogous
to those obtained in HeLa cells treated with the pan-
c a s p a s ei n h i b i t o r ,Z V A D( F i g u r e3 Aa n d3 B ) .W ec o n -
clude that Bcl-2 over-expression renders HeLa cells
resistant to MiTMAB-induced cell death, but not to
MiTMAB-induced cytokinesis failure. The involvement
of caspase-9 and Bcl-2 further indicate activation of the
intrinsic apoptotic pathway.
MiTMABs-induced cell death occurs via the intrinsic
apoptotic pathway
The activation of another initiator caspase, caspase-8, was
also detected in cells treated with MiTMABs. Unlike cas-
pase-9, caspase-8 is a component of the extrinsic apopto-
tic pathway and is thus normally activated following
stimulation of cell surface receptors [32]. Once activated,
it cleaves the pro-apoptotic Bcl-2 family member, Bid,
which in turn stimulates the intrinsic apoptotic pathway
to promote cytochrome c release from mitochondria
Figure 3 MiTMABs induce caspase activation specifically in
cells undergoing mitosis.G 2/M and G1/S synchronized cells were
treated for 8 h with 10 µM MiTMAB, 10 µM OcTMAB or indicated
controls (untreated, 0.1% DMSO and 10 µM 2-(DiMA)EM). The lysates
(prepared in duplicate) were immunoblotted for cleaved caspase-8,
-9, -3 and PARP. These cleaved products were observed in cells
treated with MiTMABs that had been synchronized at the G2/M, but
not the G1/S boundary. Lysates prepared from cells exposed to UV
served as a positive control. b-actin levels were used as a loading
control.
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pase-9/-3 in a feedback loop to amplify the already active
intrinsic pathway [36]. Therefore, we sought to determine
if activation of caspase-8 in response to MiTMABs
occurs following stimulation of the extrinsic pathway
(cell surface death receptors) and/or via intrinsic cell
death signals. We first investigated the ability of MiT-
MABs to induce apoptosis in the presence of the cas-
pase-8 selective inhibitor IETD. If the intrinsic pathway
was solely induced by caspase-8, inhibiting caspase-8
alone should block cytochrome c release and subsequent
cell death. However, inhibition of caspase-8 (IETD) only
blocked apoptosis by approximately 40% (23.3 ± 0.3%
HeLa cells treated with 30 μM OcTMAB + IETD com-
pared to 38.3 ± 0.8% in HeLa cells treated with 30 μM
OcTMAB alone; Figure 5A and 5B), in striking contrast
to the effect of the pan-caspase inhibitor, ZVAD (Figure
2). IETD treatment also resulted in only a modest
increase in polyploid cells (≥4N DNA content; Figure 5C
and 5D), presumably because a significant proportion of
cells that failed cytokinesis were able to undergo apopto-
sis. These findings suggest that activation of caspase-8
induced by MiTMABs is via the intrinsic pathway. Bcl-2
over-expression blocks cell death upstream of caspase-9
and -3 activation and thus caspase-8 cleavage should be
prevented in HeLa-Bcl-2 cells if it is activated exclusively
via the intrinsic pathway. In line with this idea, we did
not detect cleaved caspase-8 in MiTMAB-treated HeLa-
Bcl-2 cells (Figure 6). In contrast, caspase-8 cleavage was
detected in both HeLa and HeLa-Bcl-2 cells exposed to
UV, a known stimulant of the extrinsic pathway [31]. We
conclude that MiTMABs induce apoptosis via the
Figure 4 Over-expression of Bcl-2 protects cells from MiTMABs-induced cell death. A-D, G2/M synchronized HeLa (empty histograms) and
HeLa-Bcl-2 (filled histograms) cells were synchronized at the G2/M boundary. Once released from this block, cells treated with MiTMAB, OcTMAB
or indicated controls, were incubated for 20 h and their DNA contents analysed by flow cytometry. Representative flow cytometry histograms
show a decrease in the <2N peak and an increase in the 4N peak in HeLa-Bcl-2 cells treated with MiTMAB (filled histograms) compared to
parental HeLa cells (empty histograms; A). Graphs showing the percentage of HeLa and HeLa-Bcl-2 cells (mean ± S.D.) containing <2N (B), 4N (C)
and >4N (D) DNA contents are shown. * p < 0.05, ** p < 0.01 (Student’s t tests).
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caspase-8 via a feedback amplification loop.
The apoptotic response of cancer cells to MiTMABs
appears to correlate with expression of Bcl-2 and Mcl-1
anti-apoptotic proteins
We next aimed to confirm if MiTMABs induce apoptosis
in other cancer cell lines. We first analysed the cell cycle
profile by flow cytometry following a 48 h treatment with
OcTMAB of five cancer cell lines derived from different
tissues: HeLa (cervical), HT29 and SW480 (colon), MCF-
7 (breast) and H460 (lung). A significant increase in
apoptosis (<2N DNA content) was observed in three of
the cell lines (HeLa, HT29 and SW480) following expo-
sure to OcTMAB (Figure 7A). Apoptosis increased in a
dose-dependent manner with up to >70% of HT29 cells
undergoing apoptosis when exposed to 30 µM OcTMAB
(Figure 7A). In contrast, MCF-7 and H460 cells were lar-
gely resistant to OcTMAB-induced apoptosis with only
10.4 ± 0.1% and 23.6 ± 0.2% of cells, respectively, having
<2N DNA content at 30 µM. PARP cleavage occurred in
HeLa, HT29 and SW480 cells following exposure to
OcTMAB but not in MCF-7 and H460 cells (Figure 7B),
consistent with the flow cytometry data. In contrast,
PARP cleavage occurred in all five cell lines following
exposure to UV (Figure 7B). This is not surprising, as
unlike MiTMABs, UV can trigger apoptosis via both the
intrinsic and extrinsic pathways [31]. We conclude that
MiTMABs induce apoptosis via a caspase-dependent
mechanism in a range of cancer cells.
We next sought to gain insight into why specific cancer
cells are sensitive (HeLa, SW480 and HT29) and others
Figure 5 The caspase-8 inhibitor, IETD, only partially blocks cell death induced by MiTMABs.A - D ,G 2/M synchronized HeLa cells were
treated with MiTMABs and controls as described in the legend to Figure 2, except that the caspase-8 inhibitor, IETD, was used instead of ZVAD.
Representative flow cytometry histograms of HeLa cells treated with MiTMABs in the presence (filled histograms) and absence (empty
histograms) of IETD are shown (A). Quantitation (mean ± S.D.) of cells containing <2N (B), 4N (C) and >4N (D) DNA contents were determined
from two independent experiments. * p < 0.05, ** p < 0.01 (Student’s t tests).
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MiTMABs. We showed that HeLa cells stably expressing
the anti-apoptotic protein, Bcl-2, are resistant to apopto-
sis induced by MiTMABs. Moreover, Bcl-2 family mem-
bers are frequently over-expressed in cancers and confer
resistance to anti-mitotic chemotherapy in various
tumour types [37,38]. Therefore, we analysed the expres-
sion levels of three anti-apoptotic Bcl-2 family members,
Bcl-2, Bcl-XL and Mcl-1, in all five cancer cell lines.
Immunoblotting revealed that the three lines which are
sensitive to MiTMABs, HeLa, HT29 and SW480, have
relatively low levels of Bcl-2 and Mcl-1 (Figure 7C),
which correlated well with the ability of MiTMABs to
induce apoptosis in these cells. Although the MiTMABs-
resistant MCF-7 cells also expressed low levels of these
proteins (Figure 7C), their resistance can likely be
explained by their underlying deficiency in caspase-3
[39]. In contrast, high levels of Bcl-2 and Mcl-1 proteins
were detected in H460 cells (Figure 7C). Again, this cor-
related well with resistance of this cell line to MiTMABs-
induced apoptosis. Except for HeLa cells, which
expressed almost undetectable levels of Bcl-XL, the other
four cell lines expressed moderate levels (Figure 7C).
Thus, unlike Bcl-2 and Mcl-1, Bcl-XL protein levels did
not correlate well with sensitivity to MiTMABs. The
Figure 6 Caspase-8 activation in MiTMAB treated cells occurs
downstream of caspase-9/3 activation.G 2/M synchronized HeLa-
Bcl-2 cells were treated with MiTMABs and controls as described in
the legend to Figure 5. Following an 8 h exposure to MiTMABs,
lysates (prepared in duplicate) were immunoblotted for caspase-8.
In contrast to HeLa cells (Figure 3), cleaved caspase-8 was not
observed in HeLa-Bcl-2 cells treated with MiTMABs. Lysates prepared
from UV treated HeLa and HeLa-Bcl-2 cells were used as a positive
control. b-actin served as a loading control.
Figure 7 Cancer cells expressing high levels of Bcl-2 are
resistant to apoptosis induced by MiTMABs. A-B, Asynchronously
growing HeLa, HT29, SW480, MCF-7 and H460 cells were treated
with the indicated concentration of OcTMAB for 48 h. Cells
containing <2N DNA content (mean ± S.D. from two independent
experiments) were determined by flow cytometry (A) and the
presence of cleaved PARP was assessed by immunoblotting (B). C,
Expression levels of the Bcl-2 family members, Bcl-2, Mcl-1 and Bcl-
XL, were assessed and compared in the indicated cancer cell lines
by immunoblotting. b-actin served as a loading control.
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apoptosis appears to be dependent on the relative expres-
sion levels of the anti-apoptotic proteins Bcl-2 and Mcl-1.
Discussion
Dynamin inhibitors are a new class of targeted anti-
mitotic compounds. In contrast to the classical (e.g.
taxol) and known targeted (e.g. Aurora kinase and Plk
inhibitors) anti-mitotic compounds which aim to disrupt
the mitotic spindle, the MiTMAB dynamin inhibitors
exclusively block cytokinesis without disrupting progres-
sion through any other stage of mitosis. Analogous to
other anti-mitotic compounds, dynamin inhibitors also
have putative anti-tumour activity [4]. In this study, we
show that two dynamin inhibitors called the MiTMABs
induce cytokinesis failure and induce apoptosis in cancer
cells and this appears to correlate with low expression of
the anti-apoptotic proteins Bcl-2 and Mcl-1. Apoptosis
occurred strictly following formation of a polyploid cell
and was mediated via the intrinsic pathway. Over-
expression of the anti-apoptotic protein, Bcl-2, blocked
MiTMAB-induced apoptosis but not polyploidization.
The induction of apoptosis exclusively following mitotic
damage is analogous to the effect of targeted anti-mito-
tics, such as aurora kinase and Plk inhibitors [1]. We
also demonstrate that apoptosis is induced in cells that
have failed cytokinesis due to treatment with the cyto-
kinesis blocker, cytochalsin B. Therefore, this is the first
study to demonstrate that cytokinesis blockers can spe-
cifically induce apoptotic cell death and thus represent a
new class of anti-mitotics with potential anti-cancer
activity. Our results indicate that dynamin II is the pri-
mary target in this new anti-mitotic action.
Cells exposed to MiTMAB undergo cell death via acti-
vation of the intrinsic apoptotic pathway. This was evi-
dent by the presence of cleaved caspase-3, -9, and PARP,
an increase in DNA fragmentation (<2N DNA content),
and membrane blebbing. We further demonstrate that
this intrinsic apoptotic pathway involves a feedback cas-
pase-8 amplification loop to drive the execution of apop-
tosis. MiTMAB-induced cell death exclusively occurred
following cytokinesis failure and subsequent polyploidiza-
tion. This was demonstrated by several findings. Indepen-
dent single cell analysis using time-lapse microscopy
revealed that those MiTMAB-treated cells that failed
cytokinesis subsequently underwent apoptotic cell death.
We observed an increase in polyploidization in MiT-
MAB-treated cells when apoptosis was blocked by ZVAD
or Bcl-2 overexpression. Caspase-8, -9, -3 and PARP clea-
vage products were not observed in cells treated with
MiTMABs that were not able to undergo a mitotic divi-
sion (8 h treatment from G1/S synchronization). Similar
reports of cell death specifically following polyploidiza-
tion in the presence of targeted inhibitors, such as aurora
kinase, Plk and KSP inhibitors, have been reported
[1,2,40]. This indicates that inhibition of a specific target
is not the trigger for apoptosis but rather that it is the
phenotype or subsequent molecular alteration generated
as a result of its disruption.
The ability of anti-mitotic compounds to induce apop-
tosis exclusively in dividing cells is the primary rationale
that they may be efficacious chemotherapeutic com-
pounds [3,19,20,41]. However, an increased level of poly-
ploidization does not appear to translate into increased
level of secondary apoptosis [42]. Rather the resulting
induction of apoptosis appears to be cell type specific. In
line with this idea, the cellular response following expo-
sure to a particular anti-mitotic varies and includes not
only apoptosis, but also mitotic catastrophe, senescence
and reversible mitotic arrest [25]. One determinant
thought to predict the cellular response to a particular
anti-mitotic is the time spent blocked in mitosis [43]. In
the presence of the microtubule-stabilising drugs,
ZM447439 (Aurora A/B inhibitor) and taxol, cells
blocked in mitosis for >15 h undergo apoptosis shortly
after mitotic exit, whereas those cells blocked in mitosis
for <15 h showed variable fates with some cells living for
days after mitotic exit [43]. This analysis was carried out
in HeLa cells, as done in the present study. In contrast to
these findings, the MiTMABs, which block cytokinesis,
did not trap cells at this mitotic stage for a long period of
time, but only slightly delayed mitotic exit by approxi-
mately 30 mins [4]. Nevertheless, time-lapse analysis
indicated that every MiTMAB treated HeLa cell failing
cytokinesis proceeded to apoptotic cell death approxi-
mately 7-10 hours after exiting mitosis. Conversely, we
have previously shown that H460 cells spend a prolonged
period of time trapped in cytokinesis in the presence of
MiTMABs (up to 24 h) [4] and these cells remained
viable during the following 24 h time period of analysis.
Thus, in the case of the MiTMAB-based dynamin inhibi-
tors, the induction of apoptosis appears to correlate with
a short (rather than long) period of time that cells spend
trapped in cytokinesis. The significance of this correla-
tion needs to be investigated in more detail. Rather, the
difference in apoptotic response between these two cell
lines likely represents the underlying difference in their
molecular components, such as p53 status and Bcl-2 pro-
tein levels.
Several reports suggest that p53 status is critical for
determining the cellular response following polyploidiza-
tion [21,44,45]. It is possible that MiTMAB-induced cell
death is influenced by p53 status since its expression or
mutation status also correlated with sensitivity (HeLa:
p53
wt but almost undetectable levels due to HPV, HT29:
p53
mut and SW480: p53
mut) and resistance (MCF-7 and
H460 contain p53
wt) to apoptosis. Given that this gene is
frequently lost or mutated in cancers [46], the ability of
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ploidization in cells lacking functional p53 could be a
favourable characteristic as a potential chemotherapeutic
agent. It could be particularly relevant to those drug
resistant cancers that often develop following p53 muta-
tion. However, the contribution of p53 in determining
the cellular response following polyploidization is under
debate and is complicated by its multiple roles. For
example, in response to aurora kinase inhibitors, p53
wt is
required for G1 arrest of tetraploid cells [21] and for
inducing apoptosis following tetraploid formation [45].
Therefore, p53 status alone is not the sole predictor of
the cellular response following polyploidization.
The expression of Bcl-2 and Mcl-1, but not Bcl-XL,
appears to correlate with the ability of cells to undergo
apoptosis following exposure to MiTMABs. There are
six anti-apoptotic Bcl-2 family members identified and
several of these appear to contribute to drug resistance
in cancer cells [37,38], suggesting that inhibition of mul-
tiple Bcl-2 family members will be necessary to achieve
an optimal therapeutic effect. The development of
antagonists toward Bcl-2 [47] and Mcl-1 [48] provide an
attractive hypothesis that MiTMABs may synergise with
these antagonists to sensitise resistant cell lines to
undergo apoptosis. In line with this idea, the Bcl-2
antagonists, ABT-737 or ABT-263, have been shown to
synergise with Plk and aurora kinase inhibitors [49] as
well as conventional chemotherapeutic drugs, such as
vincristine, in vitro and in vivo [50].
Conclusions
Overall, our findings demonstrate that the MiTMAB
family of dynamin inhibitors induce apoptosis in a con-
centration-dependent manner following polyploidization.
More specifically, these are the first reported targeted
anti-mitotic compounds which induce polyploidy by
exclusively blocking cytokinesis. Thus, dynamin inhibi-
tors are a new class of anti-mitotic compounds with
potential anti-cancer action. MiTMAB-induced apoptosis
is not only dependent on cytokinesis failure and polyploi-
dization but also on specific molecular components of
the apoptotic machinery, such as Bcl-2. Thus, inhibitors
of these anti-apoptotic proteins, such as the Bcl-2 inhibi-
tor ABT-737, may act synergistically with the MiTMAB
dynamin inhibitors, broadening their therapeutic poten-
tial for the treatment of cancer.
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